Harry R Owens Jr, MD in Nome, AK - General Practice

Harry R Owens Jr, MD is a General Practice physician based in Nome, Alaska. Harry R Owens Jr is licensed to practice in Alaska (license number 806) and his current practice location is 306 West 5th Ave, Nome, Alaska. He can be reached at his office (for appointments etc.) via phone at (901) 443-3311.

NPI number for Harry R Owens Jr is 1467795419 and his current mailing address is Po Box 417, Blue River, Oregon. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1467795419.

Contact Information

	Harry R Owens Jr, MD
	306 West 5th Ave, Nome, AK 99762
	(901) 443-3311
	Not Available

Physician's Profile

Full Name	Harry R Owens Jr
Gender	Male
Speciality	General Practice
Location	306 West 5th Ave, Nome, Alaska
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1467795419
Provider Enumeration Date: 03/28/2013
Last Update Date: 03/28/2013

Medical Identifiers

Medical identifiers for Harry R Owens Jr such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1467795419	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	806 (Alaska)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Harry R Owens Jr is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Harry R Owens Jr, MD Po Box 417, Blue River, OR 97413-0417 Ph: () -	Harry R Owens Jr, MD 306 West 5th Ave, Nome, AK 99762 Ph: (901) 443-3311

News Archive

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Inhibitex, Inc. today reported top-line safety and efficacy data from its Phase II clinical trial of FV-100, an oral antiviral compound being developed to treat herpes zoster, more commonly referred to as shingles. The study was the first clinical trial to assess the antiviral activity of FV-100, included 350 shingles patients and compared two once-daily doses of FV-100 (200 mg and 400 mg) to an active control, valacyclovir, one of the most commonly-used antiviral drugs to treat shingles.

Reovirus can trick the body's defenses to reach and kill cancer cells

Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumors undetected by hitching a ride on blood cells.

Possible link between outdoor food ads and a tendency to pack on pounds

Past studies have suggested a relationship between neighborhood characteristics and obesity, as well as a connection between obesity and advertisements on television and in magazines.

Research offers molecular details of pancreatic cancer's ability to invade and evade

Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.

Clinical trial proves ‘inside the artery' therapy improves patient outcomes after stroke

"This clinical trial proves beyond any doubt that inside the artery therapy is the best possible treatment for patients suffering an acute ischemic stroke from a large artery occlusion," according to Donald Frei, MD, Neuro Interventional Surgeon at Swedish Medical Center and Radiology Imaging Associates in Englewood, CO.

Harry R Owens Jr, MD - General Practice in Nome, AK